M
Megumi Tasaka-Fujita
Researcher at Tokyo Medical and Dental University
Publications - 13
Citations - 593
Megumi Tasaka-Fujita is an academic researcher from Tokyo Medical and Dental University. The author has contributed to research in topics: Interferon & Hepatitis C virus. The author has an hindex of 8, co-authored 13 publications receiving 528 citations. Previous affiliations of Megumi Tasaka-Fujita include National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Antiviral effects of the interferon-induced protein guanylate binding protein 1 and its interaction with the hepatitis C virus NS5B protein.
Yasuhiro Itsui,Naoya Sakamoto,Sei Kakinuma,Mina Nakagawa,Yuko Sekine-Osajima,Megumi Tasaka-Fujita,Yuki Nishimura-Sakurai,Gouki Suda,Yuko Karakama,Kako Mishima,Machi Yamamoto,Takako Watanabe,Mayumi Ueyama,Yusuke Funaoka,Seishin Azuma,Mamoru Watanabe +15 more
TL;DR: Binding of the HCV‐NS5B protein to GBP‐1 countered the antiviral effect by inhibition of its GTPase activity, which may contribute to resistance to innate, IFN‐mediated antiviral defense and to the clinical persistence of HCV infection.
Journal ArticleDOI
Hepatitis C virus NS4B protein targets STING and abrogates RIG-I-mediated type I interferon-dependent innate immunity.
Sayuri Nitta,Naoya Sakamoto,Naoya Sakamoto,Mina Nakagawa,Sei Kakinuma,Kako Mishima,Akiko Kusano-Kitazume,Kei Kiyohashi,Miyako Murakawa,Yuki Nishimura-Sakurai,Seishin Azuma,Megumi Tasaka-Fujita,Yasuhiro Asahina,Mitsutoshi Yoneyama,Takashi Fujita,Mamoru Watanabe +15 more
TL;DR: NS4B suppresses RIG‐I–mediated IFN‐β production signaling through a direct protein interaction with STING, which may restore cellular antiviral responses and may constitute a novel therapeutic strategy for the eradication of HCV.
Journal ArticleDOI
Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features
Fukiko Kawai-Kitahata,Yasuhiro Asahina,Shinji Tanaka,Sei Kakinuma,Miyako Murakawa,Sayuri Nitta,Takako Watanabe,Satoshi Otani,Miki Taniguchi,Fumio Goto,Hiroko Nagata,Shun Kaneko,Megumi Tasaka-Fujita,Yuki Nishimura-Sakurai,Seishin Azuma,Yasuhiro Itsui,Mina Nakagawa,Minoru Tanabe,Shinichi Takano,Mitsuharu Fukasawa,Minoru Sakamoto,Shinya Maekawa,Nobuyuki Enomoto,Mamoru Watanabe +23 more
TL;DR: Gene alterations in Tert promoter, TP53, CTNNB1, and HBV integration were closely associated with HCC development, and mutations in TERT promoter are related to poor prognosis.
Journal ArticleDOI
25-hydroxyvitamin D3 suppresses hepatitis C virus production
Takuya Matsumura,Takanobu Kato,Nao Sugiyama,Megumi Tasaka-Fujita,Asako Murayama,Takahiro Masaki,Takaji Wakita,Michio Imawari +7 more
TL;DR: 25(OH)D3 is a novel anti‐HCV agent that targets an infectious viral particle assembly step and provides insight into the improved efficacy of anti-HCV treatment via the combination of vitamin D3 and IFN.
Journal ArticleDOI
Inhibition of Hepatitis C Virus Replication by a Specific Inhibitor of Serine-Arginine-Rich Protein Kinase
Yuko Karakama,Naoya Sakamoto,Yasuhiro Itsui,Mina Nakagawa,Megumi Tasaka-Fujita,Yuki Nishimura-Sakurai,Sei Kakinuma,Masaya Oooka,Seishin Azuma,Kiichiro Tsuchiya,Hiroshi Onogi,Masatoshi Hagiwara,Mamoru Watanabe +12 more
TL;DR: It is shown that an SRPK inhibitor, SRPIN340, suppressed in a dose-dependent fashion expression of a hepatitis C virus (HCV) subgenomic replicon and replication of the HCV-JFH1 clone in vitro.